Statins as anti-inflammatory therapy in HIV disease?

Journal of Infectious Diseases

Volumn 203, Issue 6, 2011, Pages 751-752

  Carr, Andrew ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CD38 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHOLESTEROL; GAMMA INTERFERON; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; KRUPPEL LIKE FACTOR 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; VIRUS RNA;

ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CHEMOTAXIS; CHOLESTEROL SYNTHESIS; DISEASE COURSE; DRUG MECHANISM; DRUG MEGADOSE; EDITORIAL; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; LIPOLYSIS; LYMPHOCYTE PROLIFERATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VIRUS LOAD; VIRUS REPLICATION;

ANTI-INFLAMMATORY AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79952353156     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq120     Document Type: Editorial

References (21)

1. Baigent C. Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
2. Ridker PM, Rifai N, Clearfield M. et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959-65. (Pubitemid 32568149)
3. Albert MA, Danielson E, Rifai N, Ridker PM. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70. (Pubitemid 32606333)
4. Nissen SE, Tuzcu EM, Schoenhagen P, et al; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
5. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Trial Study Group. Reduction in C-reactive protein, and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175-82.
6. Bu DX, Tarrio M, Grabie N, et al. Statin-induced Krüppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J Clin Invest 2010; 120:1961-70.
7. Singh P, Kohr D, Kaps M, Blaes F. Influence of statins on MHC class I expression. Ann N Y Acad Sci 2009; 1173:746-51.
8. Montecucco F, Burger F, Pelli G, et al. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatol 2009; 48:233-42.
9. Mira E, León B, Barber DF, et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J Immunol 2008; 181:3524-34.
10. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005; 26:883-91. (Pubitemid 41214316)
11. Mulhaupt F, Matter CM, Kwak BR, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003; 59:755-66. (Pubitemid 38368692)
12. Mazière JC, Landureau JC, Giral P, et al. Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother 1994; 48:63-7. (Pubitemid 24113551)
13. Giguère JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004; 78:12062-65. (Pubitemid 39390792)
14. Moncunill G, Negredo E, Bosch L, et al. Evaluation of the anti-HIV activity of statins. AIDS 2005; 19:1697-700. (Pubitemid 41502686)
15. Amet T, Nonaka M, Dewan MZ, et al. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect 2008; 10:471-80.
16. Negredo E, Clotet B, Puig J, et al. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. AIDS 2006; 20:619-21. (Pubitemid 43731608)
17. Ganesan A, Crum-Cianflone NF, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1-RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011. (in this issue).
18. Fehr T, Kahlert C, Fierz W, et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004; 175:83-90. (Pubitemid 38746913)
19. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:83-92.
20. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-70. (Pubitemid 29159331)
21. Giorgi JV, Lyles RH, Matud JL, et al. Multicenter AIDS Cohort Study. Predictive value of immunologic, and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29:346-55. (Pubitemid 34288887)